News12 Jan 2026 11:11
Enalytix plc (RENX.LN)*, Futura Medical plc (FUM.LN) Non-Independent Research; Marketing & Sales Commentary - MiFID II exempt information – see disclaimer below. Company Update: 12 January 2026 Renalytix plc (LSE: RENX, OTCQB: RNLXY)*: Three kidneyintelX.dkd clinical integration – update on Tempus collaboration Market Capitalisation: £26.6m; Share Price: 6.08p • During the last quarter of 2025, Renalytix completed three additional kidney specialist healthcare provider clinical integrations in the US, in New York, Florida and Tennessee. • Additional integrations are expected in early 2026. • Tempus collaboration is progressing well with teams from both Tempus and Renalytix working closely to target Tempus’ customers with a large diabetes and kidney disease patients. Renalytix reports that it added three new US clinical integrations in late 2025, bringing its FDAapproved kidneyintelX.dkd test into established kidney care practices in New York, Florida, and Tennessee. Testing has begun at all sites, and although initial volumes are expected to be small, the company anticipates usage to build as clinicians become familiar with the workflow. More integrations are planned for early 2026. Renalytix states that it is working intensively with Tempus to integrate its kidney risk testing into major US health systems through Tempus' integrated electronic health records (EHR). Since the partnership began in September 2025, teams from both companies have been coordinating to target large provider networks with significant diabetes and CKD populations, aiming to streamline test ordering and strengthen data collection. The collaboration is positioned as a foundation for expanding into new clinical and geographic markets as the platform matures. From a strategic standpoint, this fits neatly with Renalytix’s strategy to have kidneyintelX.dkd test integrates into healthcare providers’ EHRs, which allows quick and seamless ordering. shift toward disciplined, system-level integrations rather than chasing individual clinics. The Tempus partnership could prove far more meaningful if it unlocks access to large, data-rich health systems where adoption can scale. SP Angel acts as Nomad and Broker to the Renalytix Futura Medical plc (AIM: FUM): Positive results from WSD4000 early feasibility study Market Capitalisation: £9.1m; Share Price: 1.58p • Statistically significant improvement achieved in female sexual function with WSD4000 in a study enrolling 12 women suffering from some degree of sexual dysfunction. • Results give the Company confidence to proceed to the next steps of designing a Phase III placebo-controlled trial, with results expected mid-2026 Futura reports that its WSD4000 early feasibility study in 12 women showed a clear and statistically significant improvement in sexual function, with gains on the Female Sexual Function Index (FSFI) scale well above the accepted threshold for clinical relevance. Benefits were seen across arousal
Sign In
Follow the stocks
